Caroline Rodrigues Chaves dos Reis

Caroline Rodrigues Chaves dos Reis

Auto-generated profile, based on publicly available information

Caroline Rodrigues Chaves dos Reis

Fundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós‐Graduação em Pesquisa Translacional em Fármacos e Medicamentos Rio de Janeiro RJ Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
CRCaroline Rodrigues Chaves dos Reis
Caroline Rodrigues Chaves dos Reis
HSHellen Valério Chaves Moura de Souza
Hellen Valério Chaves Moura de Souza
RLRennan Papaleo Paes Leme
Rennan Papaleo Paes Leme
FBFrederico Silva Castelo Branco
Frederico Silva Castelo Branco
TFTACIO VINICIO AMORIM FERNANDES
TACIO VINICIO AMORIM FERNANDES
LHLucas Villas Bôas Hoelz
Lucas Villas Bôas Hoelz
There are only two drugs for the treatment of Chagas disease, namely, nifurtimox and benznidazole, that can cause several adverse effects. Despite the effectiveness of these drugs in the disease's acute phase, they are not recognized as curative in the chronic phase, establishing the need for more effective treatment in all stages of the disease. Cruzain is an enzyme that plays a vital role in the life cycle of the etiologic agent, the protozoan Trypanosoma cruzi, being relevant as a therapeutic target in the planning of new drugs. Using molecular docking and dynamics simulations, we have investigated the structural and dynamic factors that can be involved in the enzyme inhibition process at the atomic-molecular level by benzimidazole compounds that are potent cruzain inhibitors with in vitro trypanocidal activity. The study suggests that these inhibitors bind cruzain through steric and hydrogen bonding interactions without altering its secondary structure content and protein compaction. Besides, we observed that these inhibitors decrease the correlation of movements between Cα-atoms of cruzain, increasing the number of atomic communities, mainly in the α-helix that presents the catalytic Cys25 residue. As expected, we also observed a correlation between the inhibitory activity of each inhibitor and their respective binding-free energies, reinforcing that the affinity of the complexes seems to be a relevant factor for enzymatic inhibition. Hence, the results presented in this work contribute to a better understanding of the cruzain enzyme inhibition mechanism through competitive and non-covalent inhibitors. Communicated by Ramaswamy H. Sarma

14 June 2026 in Chemical Biology & Drug Design
Verified
Journal Article
Open access
CRCaroline Rodrigues Chaves dos Reis
Caroline Rodrigues Chaves dos Reis
HSHellen Valério Chaves Moura de Souza
Hellen Valério Chaves Moura de Souza
LPLidia Corrêa Parra
Lidia Corrêa Parra
GSGuilber Valério Chaves Moura de Souza
Guilber Valério Chaves Moura de Souza
BZBruna Costa Zorzanelli
Bruna Costa Zorzanelli
TFTACIO VINICIO AMORIM FERNANDES
TACIO VINICIO AMORIM FERNANDES
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.